

Table S2. Survival data for all trials and trial arms grouped according to the year of trial enrollment completion assessed with platinum sensitivity

Platinum resistance

Item	Overall n = 16	2nd/3rd-line (up to April2003) n = 6	2nd/3rd-line (April2003 and later) n = 10
PFS(months)			
Median (Range)	4.4 (2.3 – 6.7)	5.2 (4.6 – 6.0)	3.7 (2.3 – 6.7)
PPS(months)			
Median (Range)	8.5 (5.7 – 10.4)	8.1 (6.0 – 8.8)	9.2 (5.7 – 10.4)
OS(months)			
Median (Range)	12.9 (8.5 – 16.6)	12.9 (12.0 - 14.0)	13.0 (8.5 – 16.6)
PPS/OS (%)			
Median (Range)	64.9 (50.0 – 77.0)	60.3 (50.0 – 65.5)	71.3 (56.0 – 77.0)

Platinum sensitive

Item	Overall n = 17	2nd/3rd-line (up to April2003) n = 9	2nd/3rd-line (April2003 and later) n = 8
PFS(months)			
Median (Range)	9.4 (4.0 – 22.0)	10.4 (5.8 – 22.0)	7.7 (4.0 – 12.0)
PPS(months)			
Median (Range)	14.9 (3.6 – 34.0)	16.0 (3.6 – 34.0)	14.0 (7.8 – 23.6)
OS(months)			
Median (Range)	24.0 (12.8 – 53.0)	25.8 (13.9 - 53.0)	20.6 (12.8 – 33.0)
PPS/OS (%)			
Median (Range)	61.3 (25.6 – 71.5)	58.3 (25.6 – 70.8)	65.2 (55.6 – 71.5)